{"id":5174,"date":"2024-02-02T12:34:07","date_gmt":"2024-02-02T12:34:07","guid":{"rendered":"https:\/\/www.value-dx.eu\/?p=5174"},"modified":"2024-04-22T12:34:30","modified_gmt":"2024-04-22T12:34:30","slug":"value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2","status":"publish","type":"post","link":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/","title":{"rendered":"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections"},"content":{"rendered":"

[av_section min_height=” min_height_pc=’25’ min_height_px=’500px’ padding=’default’ shadow=’no-border-styling’ bottom_border=’no-border-styling’ bottom_border_diagonal_color=’#333333′ bottom_border_diagonal_direction=” bottom_border_style=” custom_margin=’0px’ custom_margin_sync=’true’ custom_arrow_bg=” id=” color=’main_color’ background=’bg_color’ custom_bg=’#08b4a0′ background_gradient_color1=” background_gradient_color2=” background_gradient_direction=’vertical’ src=” attachment=” attachment_size=” attach=’parallax’ position=’top center’ repeat=’stretch’ video=” video_ratio=’16:9′ overlay_opacity=’0.5′ overlay_color=’#08b4a0′ overlay_pattern=” overlay_custom_pattern=” av_element_hidden_in_editor=’0′ av_uid=’av-jzkylawd’ custom_class=”]<\/p>\n

[av_heading heading=’VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections’ tag=’h3′ style=’blockquote modern-quote modern-centered’ subheading_active=’subheading_below’ show_icon=” icon=’ue800′ font=’entypo-fontello’ size=” av-desktop-font-size-title=” av-medium-font-size-title=” av-small-font-size-title=” av-mini-font-size-title=” subheading_size=’15’ av-desktop-font-size=” av-medium-font-size=” av-small-font-size=” av-mini-font-size=” icon_size=” av-desktop-font-size-1=” av-medium-font-size-1=” av-small-font-size-1=” av-mini-font-size-1=” color=” custom_font=” subheading_color=” seperator_color=” icon_color=” margin=” margin_sync=’true’ av-desktop-margin=” av-desktop-margin_sync=’true’ av-medium-margin=” av-medium-margin_sync=’true’ av-small-margin=” av-small-margin_sync=’true’ av-mini-margin=” av-mini-margin_sync=’true’ headline_padding=” headline_padding_sync=’true’ av-desktop-headline_padding=” av-desktop-headline_padding_sync=’true’ av-medium-headline_padding=” av-medium-headline_padding_sync=’true’ av-small-headline_padding=” av-small-headline_padding_sync=’true’ av-mini-headline_padding=” av-mini-headline_padding_sync=’true’ padding=’10’ av-desktop-padding=” av-medium-padding=” av-small-padding=” av-mini-padding=” icon_padding=’10’ av-desktop-icon_padding=” av-medium-icon_padding=” av-small-icon_padding=” av-mini-icon_padding=” link=’manually,http:\/\/’ link_target=” title_attr=” id=” custom_class=” template_class=” av_uid=’av-kx4q0z2f’ sc_version=’1.0′ admin_preview_bg=”][\/av_heading]<\/p>\n

[av_codeblock wrapper_element=” wrapper_element_attributes=” codeblock_type=” av_uid=’av-jzkypxcu’ custom_class=”]<\/p>\n

<\/div>\n

[\/av_codeblock]<\/p>\n

[\/av_section][av_section min_height=” min_height_pc=’25’ min_height_px=’500px’ padding=’default’ shadow=’no-border-styling’ bottom_border=’no-border-styling’ bottom_border_diagonal_color=’#333333′ bottom_border_diagonal_direction=” bottom_border_style=” custom_margin=’0px’ custom_margin_sync=’true’ custom_arrow_bg=” id=” color=’main_color’ background=’bg_color’ custom_bg=’#1b7ca4′ background_gradient_color1=” background_gradient_color2=” background_gradient_direction=’vertical’ src=” attachment=” attachment_size=” attach=’scroll’ position=’top left’ repeat=’no-repeat’ video=” video_ratio=’16:9′ overlay_opacity=’0.9′ overlay_color=” overlay_pattern='{{AVIA_BASE_URL}}images\/background-images\/dots-for-dark-background.png’ overlay_custom_pattern=” av_element_hidden_in_editor=’0′ av_uid=’av-1cjng’ custom_class=”]<\/p>\n

[av_one_full first min_height=” vertical_alignment=’av-align-top’ space=” margin=’0px’ margin_sync=’true’ row_boxshadow_color=” row_boxshadow_width=’10’ link=” linktarget=” link_hover=” title_attr=” alt_attr=” padding=’50px,5%,50px,5%’ highlight_size=’1.1′ border=” border_color=” radius=’0px’ radius_sync=’true’ column_boxshadow_color=” column_boxshadow_width=’10’ background=’bg_color’ background_color=” background_gradient_color1=” background_gradient_color2=” background_gradient_direction=’vertical’ src=” attachment=” attachment_size=” background_position=’top left’ background_repeat=’no-repeat’ animation=” mobile_breaking=” mobile_display=” av_uid=’av-k0i4yzrj’ custom_class=”]<\/p>\n

[av_textblock fold_type=” fold_height=” fold_more=’Read more’ fold_less=’Read less’ fold_text_style=” fold_btn_align=” textblock_styling_align=” textblock_styling=” textblock_styling_gap=” textblock_styling_mobile=” size=” av-desktop-font-size=” av-medium-font-size=” av-small-font-size=” av-mini-font-size=” font_color=” color=” fold_overlay_color=” fold_text_color=” fold_btn_color=’theme-color’ fold_btn_bg_color=” fold_btn_font_color=” size-btn-text=” av-desktop-font-size-btn-text=” av-medium-font-size-btn-text=” av-small-font-size-btn-text=” av-mini-font-size-btn-text=” fold_timer=” z_index_fold=” id=” custom_class=” template_class=” av_uid=’av-yfjs’ sc_version=’1.0′ admin_preview_bg=”]
\nAntimicrobial resistance (AMR) poses a significant global health threat, exacerbated by the irrational use of antibiotics, particularly in the treatment of respiratory tract infections in community care. Rapid Point-of-Care Tests (POCTs) can help mitigate overuse, but their adoption remains limited in most European countries. This <\/span>VALUE-Dx paper<\/span><\/a> explores the barriers and facilitators within health technology assessment (HTA), pricing, and funding policies that impact the use of POCTs for acute respiratory tract infections in outpatient practices.<\/span><\/p>\n

Results<\/b><\/p>\n

Expert interviews were conducted with representatives from five European countries: Austria, Estonia, France, Poland, and Sweden. The interviews provided comprehensive insights into HTA, funding, and pricing policies in the peri-launch phase. Barriers identified included a lack of evidence for diagnostics, limited transferability methods from medicines to diagnostics, and the absence of price regulation for studied diagnostics. Weak purchasing power due to regional procurement processes was also noted as a pricing-related obstacle. On the funding front, the coverage (reimbursement) of diagnostic tests and optimized remuneration for physicians were recognized as facilitators.<\/span><\/p>\n

Conclusion<\/b><\/p>\n

Diverse barriers and facilitators in the peri-launch phase for POCT uptake were identified, largely influenced by the country context and healthcare system. While the complex HTA process posed challenges, it wasn’t a barrier to POCT use in most countries.Free pricing was prevalent in all investigated countries, with substantial differences in funding for POCT application. Optimizing funding emerged as a key factor in increasing POCT uptake. Policymakers need to recognize that the non-adoption of peri-launch policies can impose long-term costs on the healthcare system and leave untapped potentials in pricing and funding. Measures against AMR should be integrated, acknowledging the interaction and impact of different policies. The implementation of national action plans against AMR can indirectly influence POCT uptake by addressing barriers related to funding.<\/span><\/p>\n

Read the paper here<\/b><\/a>.\u00a0<\/b>
\n[\/av_textblock]<\/p>\n

[\/av_one_full][av_one_fifth first min_height=” vertical_alignment=” space=” custom_margin=” margin=’0px’ row_boxshadow=” row_boxshadow_color=” row_boxshadow_width=’10’ link=” linktarget=” link_hover=” title_attr=” alt_attr=” padding=’0px’ highlight=” highlight_size=” border=” border_color=” radius=’0px’ column_boxshadow=” column_boxshadow_color=” column_boxshadow_width=’10’ background=’bg_color’ background_color=” background_gradient_color1=” background_gradient_color2=” background_gradient_direction=’vertical’ src=” background_position=’top left’ background_repeat=’no-repeat’ animation=” mobile_breaking=” mobile_display=” av_uid=’av-3b8mw’]<\/p>\n

[\/av_one_fifth][av_one_fifth min_height=” vertical_alignment=” space=” custom_margin=” margin=’0px’ row_boxshadow=” row_boxshadow_color=” row_boxshadow_width=’10’ link=” linktarget=” link_hover=” title_attr=” alt_attr=” padding=’0px’ highlight=” highlight_size=” border=” border_color=” radius=’0px’ column_boxshadow=” column_boxshadow_color=” column_boxshadow_width=’10’ background=’bg_color’ background_color=” background_gradient_color1=” background_gradient_color2=” background_gradient_direction=’vertical’ src=” background_position=’top left’ background_repeat=’no-repeat’ animation=” mobile_breaking=” mobile_display=” av_uid=’av-2lzlw’]<\/p>\n

[\/av_one_fifth][av_one_fifth min_height=” vertical_alignment=” space=” custom_margin=” margin=’0px’ row_boxshadow=” row_boxshadow_color=” row_boxshadow_width=’10’ link=” linktarget=” link_hover=” title_attr=” alt_attr=” padding=’0px’ highlight=” highlight_size=” border=” border_color=” radius=’0px’ column_boxshadow=” column_boxshadow_color=” column_boxshadow_width=’10’ background=’bg_color’ background_color=” background_gradient_color1=” background_gradient_color2=” background_gradient_direction=’vertical’ src=” background_position=’top left’ background_repeat=’no-repeat’ animation=” mobile_breaking=” mobile_display=” av_uid=’av-7tlo’]<\/p>\n

[av_social_share title=” style=’minimal’ buttons=’custom’ share_twitter=’aviaTBshare_twitter’ share_linkedin=’aviaTBshare_linkedin’ share_mail=’aviaTBshare_mail’ av_uid=’av-k0i4kjks’ custom_class=” admin_preview_bg=”]<\/p>\n

[\/av_one_fifth][av_one_fifth min_height=” vertical_alignment=” space=” custom_margin=” margin=’0px’ row_boxshadow=” row_boxshadow_color=” row_boxshadow_width=’10’ link=” linktarget=” link_hover=” title_attr=” alt_attr=” padding=’0px’ highlight=” highlight_size=” border=” border_color=” radius=’0px’ column_boxshadow=” column_boxshadow_color=” column_boxshadow_width=’10’ background=’bg_color’ background_color=” background_gradient_color1=” background_gradient_color2=” background_gradient_direction=’vertical’ src=” background_position=’top left’ background_repeat=’no-repeat’ animation=” mobile_breaking=” mobile_display=” av_uid=’av-1gk3g’]<\/p>\n

[\/av_one_fifth][av_one_fifth min_height=” vertical_alignment=” space=” custom_margin=” margin=’0px’ row_boxshadow=” row_boxshadow_color=” row_boxshadow_width=’10’ link=” linktarget=” link_hover=” title_attr=” alt_attr=” padding=’0px’ highlight=” highlight_size=” border=” border_color=” radius=’0px’ column_boxshadow=” column_boxshadow_color=” column_boxshadow_width=’10’ background=’bg_color’ background_color=” background_gradient_color1=” background_gradient_color2=” background_gradient_direction=’vertical’ src=” background_position=’top left’ background_repeat=’no-repeat’ animation=” mobile_breaking=” mobile_display=” av_uid=’av-yzdo’]<\/p>\n

[\/av_one_fifth][\/av_section][av_section min_height=” min_height_pc=’25’ min_height_px=’500px’ padding=’default’ shadow=’no-border-styling’ bottom_border=’no-border-styling’ bottom_border_diagonal_color=’#333333′ bottom_border_diagonal_direction=” bottom_border_style=” custom_margin=’0px’ custom_margin_sync=’true’ custom_arrow_bg=” id=” color=’main_color’ background=’bg_color’ custom_bg=’#1b7ca4′ background_gradient_color1=” background_gradient_color2=” background_gradient_direction=’vertical’ src=” attachment=” attachment_size=” attach=’scroll’ position=’top left’ repeat=’no-repeat’ video=” video_ratio=’16:9′ overlay_opacity=’0.5′ overlay_color=” overlay_pattern=” overlay_custom_pattern=” av_element_hidden_in_editor=’0′ av_uid=’av-k0i590fy’ custom_class=”]
\n[av_codeblock wrapper_element=” wrapper_element_attributes=” codeblock_type=” av_uid=’av-jzkypxcu-1′ custom_class=”]<\/p>\n

<\/div>\n

[\/av_codeblock]
\n[\/av_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

[av_section min_height=” min_height_pc=’25’ min_height_px=’500px’ padding=’default’ shadow=’no-border-styling’ bottom_border=’no-border-styling’ bottom_border_diagonal_color=’#333333′ bottom_border_diagonal_direction=” bottom_border_style=” custom_margin=’0px’ custom_margin_sync=’true’ custom_arrow_bg=” id=” color=’main_color’ background=’bg_color’ custom_bg=’#08b4a0′ background_gradient_color1=” background_gradient_color2=” background_gradient_direction=’vertical’ src=” attachment=” attachment_size=” attach=’parallax’ position=’top center’ repeat=’stretch’ video=” video_ratio=’16:9′ overlay_opacity=’0.5′ overlay_color=’#08b4a0′ overlay_pattern=” overlay_custom_pattern=” av_element_hidden_in_editor=’0′ av_uid=’av-jzkylawd’ custom_class=”] [av_heading heading=’VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of […]<\/p>\n","protected":false},"author":152,"featured_media":4733,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[3],"tags":[],"class_list":["post-5174","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"\nVALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections - value-dx<\/title>\n<meta name=\"description\" content=\"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections - value-dx\" \/>\n<meta property=\"og:description\" content=\"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/\" \/>\n<meta property=\"og:site_name\" content=\"value-dx\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-02T12:34:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-22T12:34:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/08\/shutterstock_1714915966-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1421\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Leandra\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ValueDx\" \/>\n<meta name=\"twitter:site\" content=\"@ValueDx\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Leandra\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/\"},\"author\":{\"name\":\"Leandra\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#\\\/schema\\\/person\\\/9da693a7844518fa62482abe916eba8d\"},\"headline\":\"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections\",\"datePublished\":\"2024-02-02T12:34:07+00:00\",\"dateModified\":\"2024-04-22T12:34:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/\"},\"wordCount\":1419,\"image\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.value-dx.eu\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/shutterstock_1714915966-scaled.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/\",\"url\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/\",\"name\":\"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections - value-dx\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.value-dx.eu\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/shutterstock_1714915966-scaled.jpg\",\"datePublished\":\"2024-02-02T12:34:07+00:00\",\"dateModified\":\"2024-04-22T12:34:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#\\\/schema\\\/person\\\/9da693a7844518fa62482abe916eba8d\"},\"description\":\"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.value-dx.eu\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/shutterstock_1714915966-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.value-dx.eu\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/shutterstock_1714915966-scaled.jpg\",\"width\":2560,\"height\":1421},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/2024\\\/02\\\/02\\\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.value-dx.eu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.value-dx.eu\\\/\",\"name\":\"value-dx\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.value-dx.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.value-dx.eu\\\/#\\\/schema\\\/person\\\/9da693a7844518fa62482abe916eba8d\",\"name\":\"Leandra\",\"url\":\"https:\\\/\\\/www.value-dx.eu\\\/index.php\\\/author\\\/leandra\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections - value-dx","description":"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/","og_locale":"en_US","og_type":"article","og_title":"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections - value-dx","og_description":"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.","og_url":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/","og_site_name":"value-dx","article_published_time":"2024-02-02T12:34:07+00:00","article_modified_time":"2024-04-22T12:34:30+00:00","og_image":[{"width":2560,"height":1421,"url":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/08\/shutterstock_1714915966-scaled.jpg","type":"image\/jpeg"}],"author":"Leandra","twitter_card":"summary_large_image","twitter_creator":"@ValueDx","twitter_site":"@ValueDx","twitter_misc":{"Written by":"Leandra","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/#article","isPartOf":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/"},"author":{"name":"Leandra","@id":"https:\/\/www.value-dx.eu\/#\/schema\/person\/9da693a7844518fa62482abe916eba8d"},"headline":"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections","datePublished":"2024-02-02T12:34:07+00:00","dateModified":"2024-04-22T12:34:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/"},"wordCount":1419,"image":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/08\/shutterstock_1714915966-scaled.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/","url":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/","name":"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections - value-dx","isPartOf":{"@id":"https:\/\/www.value-dx.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/#primaryimage"},"image":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/08\/shutterstock_1714915966-scaled.jpg","datePublished":"2024-02-02T12:34:07+00:00","dateModified":"2024-04-22T12:34:30+00:00","author":{"@id":"https:\/\/www.value-dx.eu\/#\/schema\/person\/9da693a7844518fa62482abe916eba8d"},"description":"Antibiotic resistance is a growing concern. The PRUDENCE and ADEQUATE trials therefore aim to assess the impact of reducing antibiotic prescriptions on the emergence of resistant antimicrobials.","breadcrumb":{"@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/#primaryimage","url":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/08\/shutterstock_1714915966-scaled.jpg","contentUrl":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/08\/shutterstock_1714915966-scaled.jpg","width":2560,"height":1421},{"@type":"BreadcrumbList","@id":"https:\/\/www.value-dx.eu\/index.php\/2024\/02\/02\/value-dx-paper-on-barriers-and-facilitators-in-pricing-and-funding-policies-of-european-countries-impacting-the-use-of-point-of-care-diagnostics-for-acute-respiratory-tract-infections-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.value-dx.eu\/"},{"@type":"ListItem","position":2,"name":"VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections"}]},{"@type":"WebSite","@id":"https:\/\/www.value-dx.eu\/#website","url":"https:\/\/www.value-dx.eu\/","name":"value-dx","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.value-dx.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.value-dx.eu\/#\/schema\/person\/9da693a7844518fa62482abe916eba8d","name":"Leandra","url":"https:\/\/www.value-dx.eu\/index.php\/author\/leandra\/"}]}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/www.value-dx.eu\/wp-content\/uploads\/2023\/08\/shutterstock_1714915966-scaled.jpg","_links":{"self":[{"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/posts\/5174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/users\/152"}],"replies":[{"embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/comments?post=5174"}],"version-history":[{"count":0,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/posts\/5174\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/media\/4733"}],"wp:attachment":[{"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/media?parent=5174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/categories?post=5174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.value-dx.eu\/index.php\/wp-json\/wp\/v2\/tags?post=5174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}